The ongoing mission of the Michigan Cancer Research Consortium (MCRC) CCOP has been to improve the oncologic health of the communities it serves by assuring access to and participation in state-of-the-art clinical trials and cancer prevention and control activities while contributing to knowledge development in the field of oncology care. Over the past 20 years, the MCRC represents a proven resource with significant potential to serve the objectives of the National Cancer Institute's NCORP program. First funded in 1994 as a single component CCOP, the MCRC is now comprised of thirteen health systems and 150+ oncology investigators from 50+ practices in three states. MCRC has registered over 7,700 patients to trials. Annual accrual approaches 400+ credits and the MCRC's organizational efficiencies are among the best models in the country. Additional value is added as the primary awardee and lead institution of the MCRC, Saint Joseph Mercy Health System, actively contributed to the National Community Cancer Centers Program (NCCCP) from 2010-2012. Participation provided MCRC with experience and growth in key areas of importance to the NCORP program by increasing access to care, participating in Cancer Care Delivery Research, and improving quality of care across the continuum and participation in biospecimen banking. MCRC has already sought resources and experiences to assure development of infrastructure to master Cancer Care Delivery Research. Our experience positions us for success given our proven track record in clinical trials and competency and strategic partnerships to be active members of the NCTN's Cancer Care Delivery Research program. This grant proposal encompasses and articulates a vision that the MCRC will be a productive member of the newly developed NCORP program.
The NCORP Community Sites will accrue patients/participants to NCI-approved cancer clinical trials and cancer care delivery research (CCDR). The MCRC, which is the largest community research consortium in the state of Michigan serving the adult populations, has successfully incorporated CCDR and has capacity to successfully assist the NCI in meeting the goals of the NCORP in a multi-state initiative.
|Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74|
|Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95|
|Press, Oliver W; Li, Hongli; SchÃ¶der, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7|
|Lara Jr, Primo N; Moon, James; Hesketh, Paul J et al. (2016) SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol 11:420-5|
|Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95|
|Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671|
|Usmani, S Z; Sexton, R; Ailawadhi, S et al. (2015) Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J 5:e334|